Bioequivalence study of domperidone suspension 1 mg/ml
Not Applicable
Recruiting
- Conditions
- ---.
- Registration Number
- IRCT20230222057495N7
- Lead Sponsor
- Sina Pishgam Darou Novin Pharmaceutical Company
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Healthy volunteers aged between 18 and 50 years
All candidates must be non-smokers
Body mass index less than 30 kg per square meter
Exclusion Criteria
Blood pressure less than 90 over 60 mm Hg or more than 140 over 90 mm Hg
Consumption of any drugs, alcohol or tobacco products within 2 weeks before receiving the drug
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Maximum plasma concentration of domperidone. Timepoint: Before taking the drug and: 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 24 hours after taking the drug. Method of measurement: Liquid Chromatography - Fluorescence.
- Secondary Outcome Measures
Name Time Method